Progress For J-Pharma’s First-In-Class LAT1 Inhibitor After FDA ‘Alignment’
Academic research-based Japanese venture kicks off pivotal clinical development phase for novel therapy for high-need indication.
Scrip - June 17, 2026

FDA Issues Warning Letter To Happiest Baby Over Unapproved Devices, Quality Failures
The FDA has issued a warning letter to infant sleep device maker Happiest Baby, citing unapproved size extensions to its SNOO sleep sacks, a hospital bundle that required separate clearance, unsanitary refurbished bassinets, and quality system failures including MDR and CAPA deficiencies.
Medtech Insight - June 16, 2026

NuraLogix Wins FDA Clearance For Two Contactless Vital Sign Measurements
NuraLogix’s Anura Mobile Core SDK received US FDA (510k) clearance for contactless measurement of pulse and respiration rate via facial blood flow analysis.
Medtech Insight - June 16, 2026

WuXi AppTec Sues to Block Pentagon Designation That Could Trigger BIOSECURE Act Restrictions
WuXi's complaint targets the evidence behind the Pentagon’s listing of the contractor as a ‘Chinese military company’ as well as the statutory thresholds for making such determinations at all.
Medtech Insight - June 16, 2026

No Single Partner: How Leading Hospital Systems Are Building Multi-Vendor AI Ecosystems
Across prominent health systems, a structural pattern is emerging: Projects like the Cleveland Clinic’s five-vendor pilot and Mayo’s proprietary frontier model indicate a trend toward multi-vendor strategies.
Medtech Insight - June 16, 2026

Third US OTC Approval In Three Weeks Goes To Amphastar’s Naloxone Spray
FDA announces approval to market Rextovy 4mg naloxone hydrochloride intranasal formulation OTC two years after Amphastar said it planned a switch NDA.
HBW Insight - June 17, 2026

Alvotech Secures Fresh Cash As FDA Milestones Mount
Alvotech’s $152m financing boosts near-term liquidity after a sharp Q1 cash decline, while funding a biosimilar pipeline that management says is approaching a key US launch inflection point.
Generics Bulletin - June 16, 2026

Egg-Based Biologics Platform Wins $23m Investor Backing
Neion Bio has raised an oversubscribed $23m Series A to advance its Raptor platform, which uses genetically engineered chicken eggs to produce complex biologics, including biosimilars.
Generics Bulletin - June 16, 2026

CinnaGen Converts Teriparatide Setback Into European Regulatory Breakthrough
CinnaGen’s first EU approval gives the Iranian biosimilars player a regulated-market foothold, turning an earlier teriparatide setback into a launch platform for Zandoriah across Europe’s increasingly competitive Forsteo biosimilar field.
Generics Bulletin - June 16, 2026

Podcast: AI Is Giving Time Back To Clinicians
As Royal Philips releases it latest international annual survey of clinician and patient attitudes to healthcare delivery in transition, Shez Partovi, the company's chief innovation officer, outlines for In Vivo how AI is spurring the pace of change.
In Vivo - June 17, 2026